Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
BioPsychoSocial Medicine
Published in: BioPsychoSocial Medicine 1/2017

Open Access 01-12-2017 | Research

Randomized, placebo-controlled, phase IV pilot study of ramosetron to evaluate the co-primary end points in male patients with irritable bowel syndrome with diarrhea

Authors: Motoko Ida, Akito Nishida, Hiraku Akiho, Yoshihiro Nakashima, Kei Matsueda, Shin Fukudo

Published in: BioPsychoSocial Medicine | Issue 1/2017

Login to get access

Abstract

Background

Global assessment allows patients to assess improvement in multiple irritable bowel syndrome (IBS) symptoms. However, it was deemed important to assess “clinically meaningful improvements, focusing on the patient’s chief complaint and the severity of major IBS symptoms” in addition to global assessment to show how ramosetron is effective for individual IBS symptoms. This is a pilot study to explore clinical endpoints focusing on the chief complaint of patients with IBS with diarrhea (IBS-D).

Methods

The same database was used in a previously reported post-marketing phase IV, randomized placebo-controlled pilot trial in male patients with IBS-D. The hypothesis is completely different from that of the other study. Patients with IBS-D diagnosed according to Rome III criteria were given either 5 μg of ramosetron (n = 47) or placebo (n = 51) once daily for 12 weeks after a one-week baseline period. To explore and examine endpoints that allow evaluation of “clinically meaningful improvements focusing on the patient’s chief complaint,” the chief complaint and its relief by this study drug were assessed in this exploratory study.

Results

Rates of patients with abdominal pain/discomfort, stool form and stool frequency which patients had as a chief complaint before administration were 34.0, 19.1 and 25.5%, respectively, in the ramosetron 5 μg group and 42.0, 18.0, and 20.0% in the placebo group. Responder rates for improvement in symptoms of the chief complaint that patients had before administration were 53.2% in the ramosetron 5 μg group and 42.0% in the placebo group at the last point. The greatest symptomatic improvement in the chief complaint in the ramosetron 5 μg group compared to the placebo group was shown with respect to stool consistency. Bristol Stool Form Scale (BSFS) scores were significantly lower in the ramosetron group than in the placebo group (4.36 ± 1.195 vs 4.85 ± 0.890 at the last point, P = 0.027) throughout the treatment period, except at week 6.

Conclusions

Ramosetron acted most effectively on stool consistency. Improvement in stool consistency is considered to be a clinically meaningful endpoint in showing how ramosetron was effective for individual IBS symptoms. (Clinicaltrials.gov ID: NCT00918411. Registered 9 June 2009).
Literature
1.
Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology. 2006;130:1377–90.CrossRefPubMed
2.
Sandler RS. Epidemiology of irritable bowel syndrome in the United States. Gastroenterology. 1990;99:409–15.CrossRefPubMed
3.
Gralnek IM, Hays RD, Kilbourne A, Naliboff B, Mayer EA. The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology. 2000;119:654–60.CrossRefPubMed
4.
Saito YA, Talley NJ, Melton III LJ, Fett S, Zinsmeister AR, Locke III GR. The effect of new diagnostic criteria for irritable bowel syndrome on community prevalence estimates. Neurogastroenterol Motil. 2003;15:687–94.CrossRefPubMed
5.
Kang JY. Systematic review: the influence of geography and ethnicity in irritable bowel syndrome. Aliment Pharmacol Ther. 2005;21:663–76.CrossRefPubMed
6.
Kanazawa M, Miwa H, Nakagawa A, Kosako M, Akiho H, Fukudo S. Abdominal bloating is the most bothersome symptom in irritable bowel syndrome with constipation (IBS-C): a large population-based Internet survey in Japan. BioPyschoSoc Med. 2016;10:19. doi:10.​1186/​s13030-016-0070-8.CrossRef
7.
Miwa H. Prevalence of irritable bowel syndrome in Japan: Internet survey uing Rome III criteria. Patients Prefer Adherence. 2008;2:143–7.
8.
Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. In: Drossman DA, Corazziari E, editors. Rome III. 3rd ed. McLean: Degnon Associates; 2006. p. 487–509.
9.
Spiller R, Aziz Q, Creed F, Emmanuel A, Houghton L, Hungin P, et al. Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut. 2007;56:1770–98.CrossRefPubMedPubMedCentral
10.
Whitehead WE, Crowell MD, Robinson JC, Heller BR, Schuster MM. Effects of stressful life events on bowel symptoms: subjects with irritable bowel syndrome compared with subjects without bowel dysfunction. Gut. 1992;33:825–30.CrossRefPubMedPubMedCentral
11.
Kanazawa M, Palsson OS, Thiwan SI, Tumer MJ, van Tilburg MA, Gangarosa LM, et al. Contributions of pain sensitivity and colonic motility to IBS symptom severity and predominant bowel habits. Am J Gastroenterol. 2008;103:2550–61.CrossRefPubMed
12.
Dunlop SP, Coleman NS, Blackshaw E, Perkins AC, Singh G, Marsden CA, et al. Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome. Clin Gastroenterol Hepatol. 2005;3:349–57.CrossRefPubMed
13.
Miyata K, Kamato T, Nishida A, Ito H, Katsuyama Y, Iwai A, et al. Pharmacologic profile of (R)-5-[(1-methyl-3-indolyl)carbonyl]-4,5,6,7-tetrahydro-1H-benzimidazole hydrochloride (YM060), a potent and selective 5-hydroxytryptamine3 receptor antagonist, and its enantiomer in the isolated tissue. J Pharmacol Exp Ther. 1991;259:15–21.PubMed
14.
Miyata K, Kamato T, Nishida A, Ito H, Yuki H, Yamano M, et al. Role of the serotonin3 receptor in stress-induced defecation. J Pharmacol Exp Ther. 1992;261:297–303.PubMed
15.
Miyata K, Ito H, Fukudo S. Involvement of the 5-HT3 receptor in CRH-induced defecation in rats. Am J Physiol. 1998;274:G827–31.PubMed
16.
Miyata K, Yamano M, Kamato T, Akuzawa S. Effect of serotonin (5-HT)3-receptor antagonists YM060, YM114 (KAE-393), ondansetron and granisetron on 5-HT4 receptors and gastric emptying in rodents. Jpn J Pharmacol. 1995;69:205–14.CrossRefPubMed
17.
Matsueda K, Harasawa S, Hongo M, Hiwatashi N, Sasaki D. A phase II trial of the novel serotonin type 3 receptor antagonist ramosetron in Japanese male and female patients with diarrhea-predominant irritable bowel syndrome. Digestion. 2008;77:225–35.CrossRefPubMed
18.
Matsueda K, Harasawa S, Hongo M, Hiwatashi N, Sasaki D. A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome. Scand J Gastroenterol. 2008;43:1202–11.CrossRefPubMed
19.
Fukudo S, Matsueda K, Haruma K, Ida M, Hayase H, Akiho H, et al. Optimal dose of ramosetron in female patients with irritable bowel syndrome with diarrhea: a randomized, placebo-controlled phase II trial. Neurogastroenterol Motil. 2017. doi:10.​1111/​nmo.​13023.PubMed
20.
Fukudo S, Kinoshita Y, Okumura T, Ida M, Akiho H, Nakashima Y, et al. Ramosetron reduces symptoms of irritable bowel syndrome with diarrhea and improves quality of life in women. Gastroenterology. 2016;150:358–66.CrossRefPubMed
21.
Fukudo S, Kinoshita Y, Okumura T, Ida M, Hayashi K, Akiho H, et al. Effect of ramosetron in female patients with irritable bowel syndrome with diarrhea: a phase III long-term study. J Gastroenterol. 2016;9:874–82.CrossRef
22.
Hirata T, Keto Y, Nakata M, Takeuchi A, Funatsu T, Akuzawa S, et al. Effects of serotonin 5-HT3 receptor antagonists on stress-induced colonic hyperalgesia and diarrhoea in rats: a comparative study with opioid receptor agonists, a muscarinic receptor antagonist and a synthetic polymer. Neurogastroenterol Motil. 2008;20:557–65.CrossRefPubMed
23.
Veldhuyzen van Zanten SJ, Talley NJ, et al. Design of treatment trial for the functional gastrointestinal disorders. In: Drossman DA et al., editors. Rome II –The functional gastrointestinal disorders. McLean: Degnon Associates; 2000. p. 577–622.
24.
Ida M, Nishida A, Akiho H, Nakashima Y, Matsueda K Fukudo S, Evaluation of the irritable bowel syndrome severity index in Japanese male patients with irritable bowel syndrome with diarrhea. BioPyschoSocial Medicine. 2017. doi:10.​1186/​s13030-017-0092-x.
25.
Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC, et al. Functional bowel disorders. Gastroenterology. 2006;130:1480–91.CrossRefPubMed
26.
Fukudo S, Ida M, Akiho H, Nakashima Y, Matsueda K. Effect of ramosetron on stool consistency in male patients with irritable bowel syndrome with diarrhea. Clin Gastroenterol Hepatol. 2014;12:953–9.CrossRefPubMed
27.
Spiegel BM, Bolus R, Agarwal N, Sayuk G, Harris LA, Lucak S, et al. Measuring symptoms in the irritable bowel syndrome: development of a framework for clinical trials. Aliment Pharmacol Ther. 2010;32:1275–91.CrossRefPubMed
28.
Mangel AW, Northcutt AR. Review article: the safety and efficacy of alosetron, a 5-HT3 receptor antagonist, in female irritable bowel syndrome patients. Aliment Pharmacol Ther. 1999;13 Suppl 2:77–82.CrossRefPubMed
29.
Chang L, Ameen VZ, Dukes GE, McSorley DJ, Carter EG, Mayer EA. A dose-rating, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS. Am J Gastroenterol. 2005;100:115–23.CrossRefPubMed
30.
31.
Fukudo S, Kaneko H, Akiho H, Inamori M, Endo Y, Okumura T, et al. Evidence-based clinical practice guidelines for irritable bowel syndrome. J Gastroenterol. 2015;50:11–30.CrossRefPubMed
32.
Thompson WG, Heaton KW, Smyth GT, Symth C. Irritable bowel syndrome in general practice: prevalence, characteristics, and referral. Gut. 2000;46:78–82.CrossRefPubMedPubMedCentral
33.
Koloski NA, Jones M, Kalantar J, Weltman M, Zaquirre J, Talley NJ. The brain-gut pathways in functional gastrointestinal disorders is bidirectional: a 12-year prospective population-based study. Gut. 2012;61:1284–90.CrossRefPubMed
34.
35.
Kux L. Department of Health and Human Services, Food and Drug Administration [docket no. FDA–2012–D–0146]: guidance for industry on irritable bowel syndrome—clinical evaluation of drugs for treatment: availability. Fed Regist. 2012;77:32124–5.
36.
Marquis P, Lasch KE, Delgado-Herrera L, Kothari S, Lembo A, Lademacher C, et al. Qualitative development of a patient-reported outcome symptom measure in diarrhea-predominant irritable bowel syndrome. Clin Transl Gastroenterol. 2014. doi:10.​1038/​ctg.​2014.​7.PubMedPubMedCentral
37.
Metadata
Title
Randomized, placebo-controlled, phase IV pilot study of ramosetron to evaluate the co-primary end points in male patients with irritable bowel syndrome with diarrhea
Authors
Motoko Ida
Akito Nishida
Hiraku Akiho
Yoshihiro Nakashima
Kei Matsueda
Shin Fukudo
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BioPsychoSocial Medicine / Issue 1/2017
Electronic ISSN: 1751-0759
DOI
https://doi.org/10.1186/s13030-017-0093-9

Other articles of this Issue 1/2017

BioPsychoSocial Medicine 1/2017 Go to the issue

Review

Psycho-oncology in Australia: a descriptive review

Research

Psychometric properties of the eating disorder examination-questionnaire in Japanese adolescents

Case report

Longitudinal course of eating disorders after transsexual treatment: a report of two cases

Review

Development and challenges of palliative care in Indonesia: role of psychosomatic medicine

Research

Tolerable pain reduces gastric fundal accommodation and gastric motility in healthy subjects: a crossover ultrasonographic study

Case report

Clinical features of atypical odontalgia; three cases and literature reviews